Delfi Diagnostics, Inc. Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Year established

2019

Location

Baltimore MD US

Primary Industry

Biotechnology

About

Founded in 2019 by co-founders Alessandro Leal, and Victor Velculescu, and based in Maryland, US, Delfi Diagnostics focuses on analyzing fragments of cell-free DNA to detect cancer accurately from a single blood sample. In June 2024, Delfi Diagnostics, Inc. raised an amount from investors Merck Global Health Innovation Fund. Delfi Diagnostics’ primary product is a blood-based test for cancer detection, which utilizes advanced machine-learning techniques to analyze fragments of cell-free DNA fragments. By employing machine learning algorithms, Delfi identifies patterns in these fragments that are indicative of cancer. The company emphasizes the ability of their test to detect previously unrecognized markers of cancer compared to existing screening methods. The company will use the June 2024 funding to support the business growth and commercialization of its cancer detection solutions.

Current Investors

Menlo Ventures, Allianz Group, Windham Venture Partners

Request a demo to show more

Primary Industry

Biotechnology

Sub Industries

Molecular Science, Genetics & Gene Therapy, Bioinformatics, Analytics & Performance Software

Website

www.delfidiagnostics.com

Verticals

Artificial Intelligence

Company Stage

Series B

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.